Dr. Reddy’s and Integra LifeSciences Enter into an Agreement to Market and Distribute DuraGen Plus® and
Suturable DuraGen® Dural Regeneration in India
Dr. Reddy's Laboratories Limited (BSE:500124, NSE:DRREDDY, NYSE:RDY) and Integra LifeSciences Holdings Corporation (NASDAQ:
IART), a leading global medical technology company, announced today that they have entered into an exclusive distribution
agreement. Under the agreement, Dr. Reddy’s will market and distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration
Matrices for use in patients in India.
M. V. Ramana, Executive Vice President and Head of Emerging Markets & India Business, Dr. Reddy’s Laboratories said, “We are
delighted to partner with Integra LifeSciences. With the launch of DuraGen, we look forward to building our presence in the segment
of regenerative technologies and making a difference to the lives of patients undergoing neurosurgery.”
“Our market-leading DuraGen products have helped more than one million patients worldwide,” said Glenn Coleman, Chief Financial
Officer and Corporate Vice President, International, Integra LifeSciences. “This collaboration will allow us to continue to expand
patient access globally and provide innovative regenerative technology solutions to neurosurgeons and patients in India.”
The DuraGen product line offers Duraplasty Solutions™ meant for the repair of the dura mater. Dura mater is a
thick membrane that surrounds the brain and spinal cord, and contains the cerebrospinal fluid (CSF).
DuraGen Plus Dural Regeneration Matrix is indicated as a dural substitute for the repair of dura mater. It offers a simple
technique for precise placement of the matrix as an onlay graft in cranial and spinal procedures, and easily conforms to the
complex surfaces of exposed neural tissue. It provides effective protection against CSF leakage with sutureless closure and is
fully resorbed and replaced by native tissue with complete dural closure.
Suturable DuraGen matrix is a versatile graft that can be sutured and is designed for repairing dural defects where mechanical
anchoring of the graft is preferred. This offers excellent suture retention with all the benefits of DuraGen Plus Matrix.
Integra's DuraGen products have been implanted in more than 1.8 million patients worldwide to effect dural closure following
neurosurgical procedures. Integra manufactures the DuraGen family of products based on its proprietary Ultra Pure Collagen™
technology platform.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -
Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of
products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our
major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr.
Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For
more information, log on to: www.drreddys.com.
About Integra LifeSciences Corporation: Integra LifeSciences Holdings Corporation, a world leader in medical technology,
is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers
innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and
tissue technologies. For more information, please visit www.integralife.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that
are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause
actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to
statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends,"
"anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,
(i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates,
persistency levels and frequency/severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks
and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.
The company assumes no obligation to update any information contained herein.
Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
SAUNAK SAVLA, +91-40- 49002135
saunaks@drreddys.com
or
MEDIA RELATIONS
CALVIN PRINTER, +91-40- 49002121
calvinprinter@drreddys.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170327005418/en/